SARS-CoV-2 Variants B.1.351 and P.I Can Elude Neutralizing Antibodies

摘要

The monoclonal antibody imdevimab blocked entry of all viral variants, while casirivimab was effective against B.I.1.7 and partially effective against B.1.351 and P.I. Variants B.1.351 and P.I were completely resistant to bamlanivimab. B.I.1.7 was blocked by all antibodies. Convalescent plasma from COVID-19 patients exhibited neutralizing activity against B.I.1.7, but less so against B.1.351 and P.I. The vast majority of plasma samples from vaccinated persons also showed limited neutralizing activity against B.1.351 and P.I, although all sera completely inhibited entry of wild-type SARS-CoV-2.